{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T08:40:04Z","timestamp":1747471204174,"version":"3.40.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017239","name":"BeiGene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12325-025-03202-x","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T06:41:10Z","timestamp":1746254470000},"page":"2937-2949","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R\/R MCL: An Extended Follow-up Analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"Lijuan","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengju","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3479-2547","authenticated-orcid":false,"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"key":"3202_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2217\/fon-2019-0844","volume":"16","author":"P Hillmen","year":"2020","unstructured":"Hillmen P, Brown JR, Eichhorst BF, et al. ALPINE: zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. Future Oncol. 2020;16:517\u201323.","journal-title":"Future Oncol"},{"key":"3202_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","volume":"9","author":"A Kumar","year":"2019","unstructured":"Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9:50.","journal-title":"Blood Cancer J"},{"key":"3202_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","journal-title":"N Engl J Med"},{"key":"3202_CR4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase\u00a02 trial. Lancet. 2018;391:659\u201367.","journal-title":"Lancet"},{"key":"3202_CR5","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","volume":"26","author":"Y Song","year":"2020","unstructured":"Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase. Clin Cancer Res. 2020;26:4216\u201324.","journal-title":"Clin Cancer Res"},{"key":"3202_CR6","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","volume":"102","author":"JR Brown","year":"2017","unstructured":"Brown JR, Moslehi J, O\u2019Brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102:1796\u2013805.","journal-title":"Haematologica"},{"key":"3202_CR7","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","volume":"3","author":"SE Coutre","year":"2019","unstructured":"Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019;3:1799\u2013807.","journal-title":"Blood Adv"},{"key":"3202_CR8","first-page":"343","volume":"109","author":"S Le Gouill","year":"2024","unstructured":"Le Gouill S, D\u0142ugosz-Danecka M, Rule S, et al. Final results and overall survival data from a phase\u00a0II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica. 2024;109:343\u201350.","journal-title":"Haematologica"},{"key":"3202_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319\u201332.","journal-title":"N Engl J Med"},{"key":"3202_CR10","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1200\/JCO.22.02830","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Opat S, D\u2019Sa S, et al. Zanubrutinib versus ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase\u00a0III ASPEN study. J Clin Oncol. 2023;41:5099\u2013106.","journal-title":"J Clin Oncol"},{"key":"3202_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/JCO.22.00510","volume":"41","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase\u00a0III trial. J Clin Oncol. 2023;41:1035\u201345.","journal-title":"J Clin Oncol"},{"key":"3202_CR12","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase\u00a02 study. Blood. 2022;139:3148\u201358.","journal-title":"Blood"},{"key":"3202_CR13","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","volume":"7","author":"L-J Deng","year":"2023","unstructured":"Deng L-J, Zhou K-S, Liu L-H, et al. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase\u00a01\/2, open-label, multicenter, single-arm study. Blood Adv. 2023;7:4349\u201357.","journal-title":"Blood Adv"},{"key":"3202_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/17512433.2021.1978288","volume":"14","author":"CS Tam","year":"2021","unstructured":"Tam CS, Ou YC, Trotman J, Opat S. Clinical pharmacology and PK\/PD translation of the second-generation Bruton\u2019s tyrosine kinase inhibitor, zanubrutinib. Expert Rev Clin Pharmacol. 2021;14:1329\u201344.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3202_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s10637-023-01376-1","volume":"41","author":"Y Song","year":"2023","unstructured":"Song Y, Zhou K, Yang S, et al. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma. Invest New Drugs. 2023;41:606\u201316.","journal-title":"Invest New Drugs"},{"key":"3202_CR16","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"3202_CR17","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.1182\/blood-2019-130570","volume":"134","author":"J Narang","year":"2019","unstructured":"Narang J, Bajpai S, Jarecha RR, et al. Comparison of CT and PET-based assessments per lugano criteria in FDG-avid lymphoma\u2014a retrospective analysis of independent review assessments. Blood. 2019;134:5277.","journal-title":"Blood"},{"key":"3202_CR18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28:935\u201345.","journal-title":"Pharmacoeconomics"},{"key":"3202_CR19","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton N. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. (Technical Support Documents). NICE Decision Support Unit; 2016. https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/94868463\/Population_adjustment_TSD_FINAL.pdf. Accessed 27 Feb 2025."},{"key":"3202_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21:111.","journal-title":"BMC Med Res Methodol"},{"key":"3202_CR21","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1016\/j.clml.2019.04.016","volume":"19","author":"D Albano","year":"2019","unstructured":"Albano D, Ferro P, Bosio G, et al. Diagnostic and clinical impact of staging 18F-FDG PET\/CT in mantle-cell lymphoma: a two-center experience. Clin Lymphoma Myeloma Leuk. 2019;19:e457\u201364.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3202_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-020-00855-9","volume":"13","author":"DH Yoon","year":"2020","unstructured":"Yoon DH, Cao J, Chen T-Y, et al. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. J Hematol Oncol. 2020;13:21.","journal-title":"J Hematol Oncol"},{"key":"3202_CR23","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132:1647\u201356.","journal-title":"Blood"},{"key":"3202_CR24","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2021-148544","volume":"138","author":"M Shadman","year":"2021","unstructured":"Shadman M, Flinn IW, Levy MY, et al. Phase\u00a02 study of zanubrutinib in BTK inhibitor-intolerant patients (Pts) with relapsed\/refractory B-cell malignancies. Blood. 2021;138:1410.","journal-title":"Blood"},{"key":"3202_CR25","doi-asserted-by":"publisher","first-page":"13204","DOI":"10.1002\/cam4.6009","volume":"12","author":"P Yang","year":"2023","unstructured":"Yang P, Cai Q-Q, Zhang W, et al. Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: a large, multicenter retrospective analysis. Cancer Med. 2023;12:13204\u201316.","journal-title":"Cancer Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03202-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03202-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T08:00:25Z","timestamp":1747468825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03202-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3202"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03202-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Lijuan Deng, Yuqin Song, Keshu Zhou, Dengju Li, Jianda Hu, Dehui Zou, Sujun Gao, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lv, Cheng Fang, Sheng Xu, Jun Zhu have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics committee approval was not required for the study. For the zanubrutinib trial, the study was designed and monitored in accordance with sponsor procedures in compliance with the ethical principles of Good Clinical Practice, International Conference on Harmonization guidelines, the Declaration of Helsinki, and applicable local regulatory requirements. All patients provided written informed consent. The protocol, any amendments, and informed consent forms were reviewed and approved by the institutional review boards\/independent ethics committees. For the orelabrutinib trial, all patients provided written informed consent [].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}